(UroToday.com) The 2022 EAU Section of Oncological Urology (ESOU) Annual Meeting included a session on the early detection and personalized management of testis cancer and a presentation by Dr. Robert Huddart discussing follow-up of early stage seminoma. Dr. Huddart notes that there are several reasons why we follow-up patients after treatment of testicular cancer, including detection of recurrence, patient assurance, detection and management of late side effects, and for research purposes. However, we must hit the sweet spot and find the balance between detection of relapse and the cost, resource use, radiation exposure, and scan anxiety associated with follow-up. According to standard UK seminoma surveillance protocol, there is a risk of 1 in 300 for a second malignancy related to imaging alone.